Gaetano Di Guida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gaetano Di Guida has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Reginelli
Precision Medicine Department, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
1 shared publication - Antonio Gambardella
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Napoli, Italy
1 shared publication - Carminia Maria Della Corte
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80131 Naples, Italy
1 shared publication - Domenico D’angiolella
Department of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, Italy
1 shared publication - Floriana Morgillo
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80131 Naples, Italy
1 shared publication - Fortunato Ciardiello
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
1 shared publication
Latest Publications
- Open Access
- 12 May 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (10) , 1717
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial
Background: Non-small-cell lung cancer (NSCLC) is a common, steady growing lung tumour that is often discovered when a surgical approach is forbidden. For locally advanced inoperable NSCLC, the clinical approach consists of a combination of chemotherapy and radiotherapy, eventually followed by adjuvant immunotherapy, a treatment that is useful but may cause several mild and severe adverse effect. Chest radiotherapy, specifically, may affect the heart and coronary artery, impairing heart function and causing pathologic changes in myocardial tissues. The aim of this study is to evaluate the damage coming from these therapies with the aid of cardiac imaging. Methods: This is a single-centre, prospective clinical trial. Patients with NSCLC who are enrolled will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before chemotherapy 3 months, 6 months, and 9–12 months after the treatment. We expect to enrol 30 patients in 2 years. Conclusions: Our clinical trial will be an opportunity not only to highlight the timing and the radiation dose needed for pathological cardiac tissue changes to happen but will also provide useful data to set new follow-up schedules and strategies, keeping in mind that, more often than not, patients affected by NSCLC may present other heart- and lung-related pathological conditions.
- 12 May 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (10) , 1717
Open AccessCARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial
Background: Non-small-cell lung cancer (NSCLC) is a common, steady growing lung tumour that is often discovered when a surgical approach is forbidden. For locally advanced inoperable NSCLC, the clinical approach consists of a combination of chemotherapy and radiotherapy, eventually followed by adjuvant immunotherapy, a treatment that is useful but may cause several mild and severe adverse effect. Chest radiotherapy, specifically, may affect the heart and coronary artery, impairing heart function and causing pathologic changes in myocardial tissues. The aim of this study is to evaluate the damage coming from these therapies with the aid of cardiac imaging. Methods: This is a single-centre, prospective clinical trial. Patients with NSCLC who are enrolled will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before chemotherapy 3 months, 6 months, and 9–12 months after the treatment. We expect to enrol 30 patients in 2 years. Conclusions: Our clinical trial will be an opportunity not only to highlight the timing and the radiation dose needed for pathological cardiac tissue changes to happen but will also provide useful data to set new follow-up schedules and strategies, keeping in mind that, more often than not, patients affected by NSCLC may present other heart- and lung-related pathological conditions.